Details for Patent: 7,531,623

Which drugs does patent 7,531,623 protect, and when does it expire?

Patent 7,531,623 protects VIBATIV and is included in one NDA.

This patent has thirty-three patent family members in eighteen countries.

Summary for Patent: 7,531,623

Patent landscape, scope, and claims:

Title:	Hydrochloride salts of a glycopeptide phosphonate derivative
Abstract:	Disclosed are hydrochloride salts of telavancin having a chloride ion content of from about 2.4 wt. % to about 4.8 wt. %. The disclosed salts have improved stability during storage at ambient temperatures compared to other hydrochloride salts. Also disclosed are processes for preparing such salts.
Inventor(s):	Liu; Jyanwei (Sunnyvale, CA), Lee; Junning (El Granada, CA)
Assignee:	Theravance, Inc. (South San Francisco, CA)
Application Number:	10/970,128
Patent Claim Types: see list of patent claims	Compound; Composition; Process;

Drugs Protected by US Patent 7,531,623

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009		DISCN	Yes	No				Y
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009		RX	Yes	Yes				Y

International Family Members for US Patent 7,531,623

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004285924
Brazil	PI0415853
Canada	2543009
Canada	2726967
China	100417661